β2-agonists group (n = 71) | Control group (n = 103) | P-value | |
---|---|---|---|
Age, years | 71.4 ± 7.3 | 70.7 ± 8.6 | 0.523 |
Gender (male) | 55 (76%) | 80 (78%) | 0.975 |
Comorbidities (HT/DL/DM/IHD) | 20/8/9/3 | 29/15/15/7 | NS |
Smoking history | 65 (92%) | 93 (90%) | 0.778 |
Surgical procedure (VATS) | 26 (37%) | 49 (48%) | 0.152 |
Lung cancer staging (I/II/III/IV) | 48/8/13/2 | 68/9/22/4 | NS |
VC, % predicted | 94.9 ± 14.6 | 98.0 ± 16.7 | 0.186 |
FEV1, % predicted | 69.6 ± 15.1 | 79.0 ± 17.0 | <0.001 |
FEV1/FVC, % | 57.9 ± 8.6 | 62.9 ± 6.8 | <0.001 |